NextPharma adding prefilled syringe manufacturing at Belgian plant

- Last updated on GMT

Related tags: Pharmacology, Clinical trial

UK-Based CMO NextPharma is adding prefilled syringe capabilities at its facility in Braine-L’Alleud in Belgium to meet growing drug industry demand.

The expansion, which will provide aseptic filling capacity for the production of both cytotoxic and non-cytotoxic drugs for Phase I and II clinical trials, is expected to be fully completed and operational in the next few months.

Earlier​ this month the European arm of US investment group Sun Capital Partners announced plans to buy the contract manufacturing organisation (CMO), citing its significant growth potential as a key driver for the move.

Speaking to Outsourcing-Pharma.com at the time NextPharma CEO Bill Wedlake said that the firm’s new owners would support both existing capacity expansion plans and help it grow through acquisitions.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us

Products

View more

Webinars